Who Has Survived Rabies and How Is It Possible?

Fewer than 30 people are known to have survived clinical rabies, and the vast majority of them were left with severe neurological damage. The most famous survivor, a 15-year-old Wisconsin girl treated in 2004, sparked a wave of optimism about a therapeutic protocol that has since failed in at least 64 other patients. The handful of survivors scattered across medical literature share a few threads in common, but the science behind their survival reveals more about how rabies outmaneuvers the immune system than about any reliable cure.

The Milwaukee Case

In September 2004, Jeanna Giese was bitten by a bat at her church in Fond du Lac, Wisconsin. Her family cleaned the wound but did not seek medical care, and she never received post-exposure prophylaxis. Weeks later she developed symptoms of clinical rabies. Her doctors at Children’s Hospital of Wisconsin, led by Rodney Willoughby, made a radical decision: they placed her in a medically induced coma using midazolam and barbiturates while administering the antiviral drugs ribavirin and amantadine, along with ketamine. The idea was to suppress brain activity and buy time for her own immune system to mount a response against the virus.

¹

Giese survived with relatively mild neurological deficits and eventually returned to school. Her treatment was written up in the New England Journal of Medicine in 2005 and quickly branded the “Milwaukee Protocol.” One crucial detail often gets lost in the retelling: before treatment even began, her blood and cerebrospinal fluid already contained neutralizing antibodies against the rabies virus. That pre-existing immune response likely mattered far more than the drugs she received.

²

Why the Milwaukee Protocol Failed Everyone Else

After the Giese case made headlines, the Milwaukee Protocol was tried around the world. The details shifted over time, but the core remained the same: induced coma, ketamine, and antivirals. Over the following two decades, no subsequent case produced documented evidence that the protocol itself was what saved the patient. At least 64 patients treated with variations of the protocol have died.

³

The uncomfortable conclusion among infectious disease specialists is that the protocol did not work even once in a reproducible way. Giese’s survival appears to have been driven by her unusual immune response to the bat-variant virus, not by the drugs she was given. Recent clinical attempts using intrathecal and intravenous monoclonal rabies antibodies in symptomatic patients have also disappointed, barely raising antibody levels in the blood or cerebrospinal fluid.

⁴

Other Survivors and What Happened to Them

Giese is not the only person to have survived clinical rabies, but she is one of very few who recovered with a reasonably functional life. A case series from India documented eight patients with laboratory-confirmed rabies who survived, but seven of them had poor functional outcomes. Only one recovered with mild deficits.

⁵

That pattern holds across the broader literature. Most rabies survivors end up with serious neurological damage and are unable to live independently. Some die within months or a few years from medical complications related to the brain injury they sustained.

²

The Indian cases are worth noting for another reason: they suggest that improved critical care facilities in rabies-endemic countries may be keeping some patients alive long enough for their immune systems to respond, even without a specific anti-rabies drug doing the heavy lifting. Better ventilators, better management of seizures and autonomic instability, and more attentive supportive care can extend the window in which the body has a chance to fight back.

How Rabies Evades the Immune System

To understand why survival is so rare, you need to understand what the virus does once it reaches the nervous system. Rabies is not like most viral infections where the immune system detects the invader early and ramps up a response. The virus has evolved a set of stealth tactics that effectively hide it from immune surveillance until it is too late.

After entering through a bite wound, the virus hijacks a transport system that nerve cells normally use to shuttle growth signals. Research has shown that rabies latches onto a receptor called p75NTR on the surface of nerve endings and rides the cell’s internal highway toward the spinal cord and brain, traveling faster than the normal cargo that uses the same route. The virus does not just passively hitch a ride; it actively speeds things up, taking fewer stops and moving at higher velocities along the axon.

⁶

Once inside the central nervous system, rabies deploys its phosphoprotein (a protein called P) to sabotage the cell’s ability to call for help. Normally, when a cell detects a virus, it sends chemical alarm signals called interferons that activate neighboring cells and recruit the immune system. The rabies P protein blocks this alarm system at multiple points. It traps the signaling molecules that interferons rely on, preventing them from reaching the cell nucleus where they would switch on defensive genes.

⁷

The P protein also targets TBK1, an enzyme that sits at the crossroads of several pathways the cell uses to detect and respond to viral invaders. When cells sense viral genetic material, TBK1 normally clusters together with helper proteins into small liquid-like droplets that amplify the immune alarm. Rabies P binds directly to TBK1 and prevents these droplets from forming, essentially cutting the wires before the alarm can ring.

⁸

The Blood-Brain Barrier Problem

Even when the immune system eventually recognizes the virus and starts producing antibodies, there is a second barrier to clearing the infection. The brain is protected by a tightly sealed network of blood vessels called the blood-brain barrier, which normally keeps most immune cells and large molecules out of brain tissue. This protection, normally a feature, becomes a fatal bug during rabies infection.

Research with laboratory-adapted rabies strains shows that when the barrier becomes more permeable, immune cells and antibodies can flood into the brain and clear the virus. In mice, a strain of rabies that naturally triggered greater blood-brain barrier permeability led to better virus clearance and improved survival. Conversely, when researchers used a steroid hormone to reduce barrier permeability in infected mice, more of them died.

⁹

Wild-type rabies, the kind that actually infects people, appears to keep the blood-brain barrier relatively intact, which is one reason antibodies generated in the bloodstream cannot reach the virus hiding in the brain. Experiments have confirmed that even when virus-neutralizing antibodies are injected intravenously, they can only clear an established brain infection if the barrier is artificially opened.

¹⁰

This may be the single most important biological reason rabies is almost always fatal once symptoms start. The immune system is not incapable of beating the virus. It simply cannot deliver its weapons to the battlefield.

Abortive Rabies and Natural Exposure

Some people appear to have been infected with rabies and survived without ever knowing they were sick. Studies in the Peruvian Amazon, where vampire bat bites are common, found that about 11% of people tested had neutralizing antibodies against rabies in their blood despite never being vaccinated. Most of those who tested positive reported having been bitten by bats. One person had a type of antibody associated with very recent infection, suggesting ongoing exposure in the community.

¹¹

This phenomenon, sometimes called “abortive rabies,” means the virus entered the body but was fought off before it could establish a lethal infection in the brain. The likely explanations include a very small dose of virus from the bite, a viral strain with lower aggressiveness, or an immune response that happened to activate quickly enough. These cases do not represent a realistic model for surviving full-blown clinical rabies, but they do confirm that rabies infection is not always a binary event of “bitten and dead” or “bitten and vaccinated.”

Not All Rabies Strains Are Equally Lethal

The virus that Jeanna Giese contracted came from a bat, and that detail matters. Bat-associated rabies variants tend to enter through the skin and are adapted for that route, whereas dog-associated variants, which cause the vast majority of human rabies deaths worldwide, may follow somewhat different pathways into the nervous system.

¹²

Laboratory experiments in mice have shown dramatic differences in lethality between virus isolates from different bat species. When injected into muscle (mimicking a natural bite), one bat species’ isolate killed 60% of mice, while another killed only about 5%. Dog-derived isolates fell in the middle.

¹³

These differences in virulence could help explain why nearly all documented unvaccinated survivors contracted rabies from bats rather than dogs. A less aggressive strain may give the immune system a longer window to respond before the virus reaches the brain. The vast majority of human rabies deaths globally come from dog bites in Africa and Asia, where the circulating strains may be more uniformly lethal.

Post-Exposure Prophylaxis and When It Fails

The real story of surviving rabies is not about treating the disease once symptoms appear. It is about the post-exposure prophylaxis regimen that, when administered properly and promptly, is extraordinarily effective. The combination of rabies immune globulin (antibodies injected directly into and around the wound site) plus a series of vaccine doses triggers both immediate passive protection and a longer-term active immune response. In animal experiments, this combination protected 100% of infected sheep, compared to only 29% survival among untreated controls.

¹⁴

Failures of post-exposure prophylaxis do occur, but a systematic review found that deviations from recommended practice were present in over half of cases where people developed rabies despite receiving some form of treatment. Severe wounds, particularly bites to the head, face, or neck, were reported in about 69% of breakthrough cases.

¹⁵

A study of post-exposure prophylaxis failures in high-burden settings found that “true” breakthrough infections, where the treatment was given correctly, on time, and to completion, are uncommon. In the cases reviewed, only about 26% of severe-wound patients received rabies immune globulin without any deviation from protocol. About 57% started treatment within two days, but less than half completed the full vaccine course.

¹⁶

In rare cases, even correctly administered prophylaxis fails because the patient’s immune system cannot respond to the vaccine. A 2021 case in Minnesota involved a man who was bitten by a bat, received proper post-exposure treatment, and still died of rabies. He had an undiagnosed blood condition that likely prevented him from producing the antibodies the vaccine was supposed to trigger.

¹⁷

Why Many Bite Victims Never Get Treatment

Globally, the biggest reason people die of rabies is not treatment failure but treatment absence. In much of sub-Saharan Africa and South Asia, the cost and logistics of completing a multi-dose vaccine course present serious barriers. A study in Tanzania found that the average medical cost for three doses of post-exposure prophylaxis was about $37, and patients also had to spend money on transportation and sometimes overnight accommodation. For rural populations earning a few dollars a day, these costs are prohibitive.

¹⁸

In Ethiopia, accessibility drops sharply with distance: only about 23% of patients living 20 or more kilometers from a health facility that stocks the vaccine made the trip.

¹⁹

Behavioral barriers compound the logistical ones. A study during a canine rabies epidemic in Peru found that misconceptions about the vaccine, fear of side effects, and negative experiences at health facilities all led people to skip or abandon their treatment courses.

²⁰

Rabies Through Organ Transplantation

One of the more alarming chapters in rabies epidemiology involves transmission through organ transplants. Because rabies can have an incubation period lasting months and early symptoms mimic many other conditions, donors have died of unrecognized rabies and passed the virus to recipients. In 2004, four transplant recipients in the United States developed encephalitis within 30 days of receiving organs from a single donor and all four died, averaging 13 days from symptom onset to death.

²¹

A 2013 case was different in an instructive way. A kidney recipient developed rabies 18 months after transplantation from a donor later confirmed to have been infected with a raccoon rabies variant. Three other recipients of organs from the same donor survived after receiving post-exposure prophylaxis once the rabies diagnosis was made.

²²

A similar cluster occurred in China in 2016, where two organ recipients were confirmed to have contracted rabies from a transplant donor and died.

²³

The diagnostic difficulty is real: early rabies symptoms like anxiety, fatigue, and vague pain at the wound site mimic many conditions, and clinicians in areas where rabies is rare often do not consider it.

²⁴

Experimental Treatments on the Horizon

Researchers have largely moved past the Milwaukee Protocol and are pursuing more targeted approaches. One promising avenue involves mRNA vaccines designed not just to generate antibodies but also to activate T cells, a branch of the immune system that can directly kill virus-infected cells. An experimental dual-target mRNA vaccine tested in mice produced about a 20-fold reduction in viral RNA in the brain within a week and triggered strong responses from both helper and killer T cells.

²⁵

Beyond vaccines, high-throughput drug screening has identified some existing FDA-approved medications that reduce rabies virus replication at low concentrations in laboratory settings. One compound called homoharringtonine, already used in cancer treatment, has shown potential, though it has not been tested in human rabies patients.

²⁶

Monoclonal antibodies against rabies are also being developed as replacements for the human rabies immune globulin currently used in post-exposure prophylaxis. The advantage is that monoclonal antibodies can be manufactured consistently and at scale, potentially reducing both cost and supply problems in the countries that need them most. Some newer designs target multiple sites on the virus to reduce the chance of immune escape, where the virus mutates in a way that makes the antibody useless. These tools are aimed more at prevention than cure. Once the virus has established itself deep in the brain, even sophisticated antibodies struggle to reach it, which brings the challenge full circle to the blood-brain barrier problem that makes clinical rabies so difficult to treat.